Yazarlar : Matarraz S, Paiva B, Diez-Campelo M, Lopez-Corral L, Perez E, Mateos MV, Giraldo P, Hernandez MT, San-Miguel JF, Orfao A.

Yayın : Haematologica

Yayın Yılı : 2012

Pubmed Linki : http://www.ncbi.nlm.nih.gov/pubmed/22511492

Konu : MDS

Literatür İçeriği :  

Abstract

Increased risk of acute myeloid leukemia/myelodysplastic syndromes following treatment has been reported in multiple myeloma, but whether dysplastic features are already present at diagnosis remains to be investigated. Using multiparameter flow cytometry, we analyzed the distribution and phenotype of bone marrow hematopoietic cells from 47 multiple myeloma patients (15 symptomatic and 32 high-risk smoldering). From the 32 smoldering myeloma patients, 18 were studied at baseline and 22 after nine cycles of Lenalidomide/Dexamethasone treatment following the QUIREDEX trial (including eight from baseline). Phenotypic alterations of bone marrow cells of 7 (47%) symptomatic and 6 (33%) smoldering myeloma patients were detected at baseline, with no differences regarding the frequency and extent of phenotypic alterations between symptomatic versus smoldering cases. Likewise, no differences were noted between smoldering myeloma patients studied at baseline versus after Lenalidomide/Dexamethasone treatment. Our results suggest that phenotypic alterations of bone marrow hematopoietic cells are often present in newly diagnosed symptomatic and smoldering multiple myeloma patients.QUIREDEX trial (NCT00480363).

Literatür Arşivi